The goal of the NHLBI Progenitor Cell Biology Consortium (PCBC) is to identify and characterize progenitor cell lineages, to direct the differentiation of stem and progenitor cells to desired cell fates, and to develop new strategies to address the unique challenges presented by the transplantation of these cells.
In this workshop session, Dr.
Dr. Jay Zhang at the University of Minnesota recently published an article in Cell Stem Cell:
Stanford University's iPSC Biobank is an NHLBI-funded iPS resource.
Contact the SCVI for specific cardiac disease phenotypes and genetic mutations available. Access the SCVI Biobank, inquire about available iPSC lines and learn how patient's cells can be reprogrammed.
See flyer, below, for additional information.
NHLBI Funding Opportunity Announcements (FOA)
Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (R41)
FOA #: RFA-HL-15-026
The PCBC is offering another specialized stem cell course on advance hESCs techniques and cardiovascular differentiation techniques at Stanford University in March 2015. Attached below are course materials from previous training sessions for your review. Please note that a bioinformatics component will be added to the first week of the course.
Platform for Sharing and Accessing Available Protocols and Reagents
The PCBC Synapse platform, in addition to storing data is a resource for the aggregation and dissemination of protocols and reagents for the consortium.
Controlling gene networks and cell fate with precision-targeted DNA-binding proteins and small-molecule-based genome readers
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notices: